![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Otonomy Snags Approval for Otiprio
Otonomy Snags Approval for Otiprio
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
The FDA has given the green light to Otonomy’s Otiprio for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.
A single-dose antibacterial, Otiprio (ciprofloxacin otic suspension) is the first product approved for this indication, according to the company.
Otonomy spokeswoman Heidi Chokeir says the company has a preliminary net sales price target of $200 to $250. The company plans to launch the product in the first quarter of 2016.
Upcoming Events
-
21Oct